354 related articles for article (PubMed ID: 34196506)
21. Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.
Hollstein MM; Dierks S; Schön MP; Bergmann A; Abratis A; Eidizadeh A; Kaltenbach S; Schanz J; Groß U; Leha A; Kröger A; Andag R; Zautner AE; Fischer A; Erpenbeck L; Schnelle M
J Med Virol; 2023 Oct; 95(10):e29122. PubMed ID: 37787583
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
23. Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study.
Hvidt AK; Guo H; Andersen R; Lende SSF; Vibholm LK; Søgaard OS; Schleimann MH; Russell V; Cheung AM; Paramithiotis E; Olesen R; Tolstrup M
BMC Immunol; 2023 Nov; 24(1):45. PubMed ID: 37974069
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
Ruetalo N; Flehmig B; Schindler M; Pridzun L; Haage A; Reichenbächer M; Kirchner T; Kirchner T; Klingel K; Ranke MB; Normann A
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960605
[TBL] [Abstract][Full Text] [Related]
25. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
26. Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series.
Connolly CM; Teles M; Frey S; Boyarsky BJ; Alejo JL; Werbel WA; Albayda J; Christopher-Stine L; Garonzik-Wang J; Segev DL; Paik JJ
Ann Rheum Dis; 2022 Feb; 81(2):291-293. PubMed ID: 34493492
[No Abstract] [Full Text] [Related]
27. Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity.
Scaglione A; Opp S; Hurtado A; Lin Z; Pampeno C; Noval MG; Thannickal SA; Stapleford KA; Meruelo D
Front Immunol; 2021; 12():719077. PubMed ID: 34394127
[TBL] [Abstract][Full Text] [Related]
28. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
30. Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail.
Drouin AC; Theberge MW; Liu SY; Smither AR; Flaherty SM; Zeller M; Geba GP; Reynaud P; Rothwell WB; Luk AP; Tian D; Boisen ML; Branco LM; Andersen KG; Robinson JE; Garry RF; Fusco DN
Viruses; 2021 Jun; 13(7):. PubMed ID: 34201591
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
[TBL] [Abstract][Full Text] [Related]
32. B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab.
Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Jahrsdörfer B; Schrezenmeier H; Ludwig C; Sattler A; Kotsch K; Chen Y; Claußnitzer A; Haibel H; Proft F; Guerra G; Durek P; Heinrich F; Ferreira-Gomes M; Burmester GR; Radbruch A; Mashreghi MF; Lino AC; Dörner T
Arthritis Rheumatol; 2022 Jun; 74(6):934-947. PubMed ID: 34962360
[TBL] [Abstract][Full Text] [Related]
33. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
34. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
35. Both Humoral and Cellular Immune Responses to SARS-CoV-2 Are Essential to Prevent Infection: a Prospective Study in a Working Vaccinated Population from Southern France.
Graça D; Brglez V; Allouche J; Zorzi K; Fernandez C; Teisseyre M; Cremoni M; Benzaken S; Pradier C; Seitz-Polski B
J Clin Immunol; 2023 Nov; 43(8):1724-1739. PubMed ID: 37606852
[TBL] [Abstract][Full Text] [Related]
36. Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients.
Cerna K; Duricova D; Hindos M; Hindos Hrebackova J; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kastylova K; Teplan V; Lukas M
J Crohns Colitis; 2022 Sep; 16(9):1347-1353. PubMed ID: 35358307
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy.
Bazzi SA; Maguire C; Holay N; Geltman J; Hurley K; DiPasquale C; Abigania M; Olson E; Ehrlich LIR; Triplett TA; Melamed E
Mult Scler Relat Disord; 2022 Dec; 68():104195. PubMed ID: 36223705
[TBL] [Abstract][Full Text] [Related]
38. Foxp3+ CD4+ regulatory T cells control dendritic cells in inducing antigen-specific immunity to emerging SARS-CoV-2 antigens.
Uraki R; Imai M; Ito M; Shime H; Odanaka M; Okuda M; Kawaoka Y; Yamazaki S
PLoS Pathog; 2021 Dec; 17(12):e1010085. PubMed ID: 34882757
[TBL] [Abstract][Full Text] [Related]
39. Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays.
Valcourt EJ; Manguiat K; Robinson A; Lin YC; Abe KT; Mubareka S; Shigayeva A; Zhong Z; Girardin RC; DuPuis A; Payne A; McDonough K; Wang Z; Gasser R; Laumaea A; Benlarbi M; Richard J; Prévost J; Anand SP; Dimitrova K; Phillipson C; McGeer A; Gingras AC; Liang C; Petric M; Sekirov I; Morshed M; Finzi A; Drebot M; Wood H
Microbiol Spectr; 2021 Dec; 9(3):e0088621. PubMed ID: 34787495
[TBL] [Abstract][Full Text] [Related]
40. mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant.
Parry H; Tut G; Bruton R; Faustini S; Stephens C; Saunders P; Bentley C; Hilyard K; Brown K; Amirthalingam G; Charlton S; Leung S; Chiplin E; Coombes NS; Bewley KR; Penn EJ; Rowe C; Otter A; Watts R; D'Arcangelo S; Hallis B; Makin A; Richter A; Zuo J; Moss P
Elife; 2021 Sep; 10():. PubMed ID: 34586068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
